Is It Time to Buy a New Vitrectomy Platform? Put DORC EVA NEXUS in the Running.

I exclusively used non-DORC surgical platforms for the first few decades of my surgical practice. I admired DORC’s innovative spirit and occasionally collaborated with them on engineering designs, but nevertheless stuck to the surgical platform I had the most experience with.

In August 2024, my vitrectomy platform had aged, and it was time for a switch. I tasked myself with balancing two apparently (but not actually) competing demands: finding a cost-effective platform that did not sacrifice safety, efficacy, or efficiency. After weighing my options, I arrived at DORC EVA NEXUS.

If you are, like I was, seeking a cutting-edge surgical platform that allows you to invest wisely, it’s time to consider DORC EVA NEXUS.

A brief review of DORC’s history shows that the company has been the vanguard of surgical innovation. I was an early adopter for 25-gauge instrumentation, and my initial exposure to such instruments were from DORC-manufactured surgical packs. The first 27-gauge instruments I worked with were DORC products. The earliest dual-blade cutter I held was designed and built by DORC.

Given this well-earned reputation for innovation (and given my own passion for engineering and design), it’s little wonder I was attracted to DORC’s commitment to pushing the boundaries of what was possible. I continued to be impressed by their innovative culture when I trialed DORC EVA NEXUS.

To illustrate via a single example DORC’s commitment to innovation, look no further than DORC EVA NEXUS’s reliance on Valve Timing Intelligence pumps, which automatically adjust pressure during surgery based on SMART IOP detection, keep surgical pressures within a predictable and easily managed range. I prefer to keep the flow low (i.e., 2 to 8 mL/minute) as I approach the retina, and this system enables me to operate under consistent conditions that, in my estimation, maximize safety and efficacy. This next-generation vacuum system also allows me to reduce my instruments’ sphere of influence, thereby empowering me to perform more precise surgeries.

In my OR, surgery with DORC EVA NEXUS is efficient. I understand some surgeons could be concerned with a dip in OR efficiency when switching platforms, as techs must adjust patterns and protocols to match new equipment. In my OR, the move from a non-DORC platform to DORC EVA NEXUS was seamless, and my techs have reported high satisfaction with the switch.

Retina specialists are rightly concerned about inflation-adjusted declining reimbursement for surgical procedures; this is especially true of those who operate in ASC settings, where margins feel as though they’ve grown tighter in the past several years. Shopping for a new vitrectomy platform represents a significant capital expenditure, and cost-conscious surgeon-businesspeople are wise to consider how long it will take before they recoup the cost of their investment.

When it was time to shop for a new surgical platform, the price point on DORC EVA NEXUS stood out to me. Knowing that the platform allowed safe and effective surgery without a sky-high price let me spend less time thinking about the financial security of my practice and more time focusing on my patients.

When I moved from my previous platform to DORC EVA NEXUS, I was compelled to balance my uncompromisingly high standards for surgical safety and efficacy with the economic realities of my clinic—all while aiming to find a corporate partner whose culture matched my passion for engineering. I landed on DORC EVA NEXUS not because it was inexpensive, but because it offered cutting-edge technology at an affordable price.

When it’s time to upgrade your OR, check out DORC EVA NEXUS. You owe it to yourself to feel the difference.

^{The statements of the author reflect only his personal opinions and do not necessarily reflect the opinions of any institution with whom he is affiliated.
The author has a contractual or other financial relationship with Carl Zeiss Meditec, Inc. and has received financial support.}